Additional information about the data, models and results are presented in the supplement in the following order. Section 1 lists the data for the illustrative example in advanced colorectal cancer (aCRC). Section 2 describes the beta distribution based prior for the between-studies correlations. Section 3 lists all details of model 1b with the derivation of the second order consistency conditions, construction of prior distributions and WinBUGS code. The relationship between NMA models and the standard surrogate model is discussed in Section 4. Additional discussion of surrogacy criteria can be found in Section 5.
DATA FOR ILLUSTRATIVE EXAMPLE IN ACRC
Tables 1 and 2 list the data for the illustrative example in advanced colorectal cancer (ACRC), introduced in Section 2 of the main manuscript. Three studies, which gave very large odds ratios (ORs) for the tumour response (TR) (marked by * in Table  1 ) were removed in the sensitivity analysis. Results of the sensitivity analysis are presented below in Section 7.
The data were modelled on the log HR scale for progression-free survival and on the log OR scale for tumour response. The within-study correlation between log OR for TR and log HR for PFS was obtained by Elia et al (2018) by bootstrapping method, from individual participant data of a RCT (reported by Hurwitz et al 1 ) comparing Bevacizumab (anti-VEGF) with chemotherapy vs. chemotherapy alone. The within-study correlation, equal -0.433, was assumed the same across treatments. and denote the number of responders and the total number of patients in the experimental arm and and denote these numbers in the control arm.
BETA DISTRIBUTION BASED PRIOR FOR THE CORRELATION
A beta distribution was used to construct prior distributions for the between-studies correlations (all models) and for the correlation between effects on treatment arms (models 2a-c). A random variable drawn from a beta distribution ∼ (1.5, 1.5) is limited to values between 0 and 1 with probability density zero on the edges and mean value of 0.5, as seen in Figure 1 (left). Transforming this variable, such as = 2 − 1, gives a distribution bounded by −1 and 1 with mean at zero, as shown in Figure  1 (right). This can be used as a prior distribution for the between-studies correlation, as in Burke et al (2016) . The resulting prior distribution for the correlation, such as +1 2 ∼ (1.5, 1.5), allows for positive and negative values of the between-studies correlation and it is relatively flat across the range of values, with the exception that values at the extreme ends of the distribution are considered extremely unlikely.
FIGURE 1 Beta distribution

DETAILS OF MODEL 1B
We assume that the treatment effect differences between treatments and in study for the two outcomes = 1, 2 (the surrogate endpoints and the final clinical outcome) are correlated and normally distributed: (1)
To take into account the network structure of the data, we assume that the correlated true treatment effects 1 and 2 within each treatment contrast follow a common distribution:
(2)
where and denote baseline (control) and experimental treatment respectively in a study , denotes the random true treatment effect (difference between the effects of treatments and ) on outcome in study and, and the are mean treatment effect differences between treatments and for each outcome .
We use the first-order consistency assumptions, as described by Lu and Ades (2009), extended here to the bivariate case. For any three treatments ( , , ), the treatment differences ( ) satisfy the following transitivity relations
Taking the expectation of the transitivity equations gives the consistency equations for the first-order moments
which represent the relationships between the treatment contrasts in the population. When = 1 is a common reference treatment in the network, the treatment effects of each treatment in the network relative to this common reference treatment 1; the ,1 are referred to as basic parameters for each outcome , with ,11 = 0 and the others are given prior distributions:
,1 ∼ (0, 10 3 ).
To assume consistency of the second-order moments, we extend the approach proposed by Lu and Ades (2009) to the bivariate case by taking variance of the transitivity equation (3), which gives
leading to the following relationship between the variances for any three treatments ( , , ) and for both outcomes = 1, 2;
which gives the second-order consistency conditions (triangle inequalities):
In addition, the following condition applies to the covariances:
which implies further constraints that are more complex than those in Eq. (8).
To ensure that prior distributions for heterogeneous variance-covariance matrices are appropriate, i.e. to maintain the secondorder consistency condition for any three treatments in the network, ancillary parameters are used, allowing the between-studies variance-covariance matrices to be represented as
where 2 and 2 are the ancillary parameters: variances of two random effects and corresponding to treatment arms and (for each outcome = 1, 2); and , ′ is their correlation coefficient. Prior distributions for the set of between-studies standard deviations for each outcome and each pair of treatments and can be given by constructing a prior distribution for a variance-covariance matrix Γ composed of the standard deviations and correlations , ′ , for , ′ = 1, 2 and , = 1, … , , where is the number of treatments in the network. For the set of values of the elements of matrix Γ, together with the relationship (10), to give a resulting set of standard deviations and correlations 1 ,2 that satisfy the second-order consistency rules (8) and (9), the matrix Γ has to be positive semi-definite. This can be achieved in a number of ways, for example by spherical decomposition as proposed by Lu and Ades (2009). Such a spherical decomposition was later applied to construct a prior distribution for a variance-covariance matrix in multivariate meta-analysis by Wei and Higgins (2013), who also investigated use of the inverse Wishart prior distribution and a separation strategy with a Cholesky decomposition.
Here we use the latter approach where Γ = 1∕2 1∕2 , where 1∕2 is a 2 × 2 diagonal matrix of the standard deviations 11 , 21 , … , 1 , 2 and is a positive semi-definite 2 × 2 matrix of correlations , ′ (block matrix consisting of × blocks that are of 2 × 2 dimension). Matrix can be represented, using the Cholesky separation strategy, as = with being a 2 × 2 upper triangular matrix. To obtain the elements of the matrix , we follow the method by Wei and Higgins (2013). The elements of the top row of the correlation matrix are where > , = 1, … , 2 − 1, = 1, … , 2 . Prior distributions are placed on the elements of matrix in such a way to ensure the correlations are constrained to the range of values between -1 and 1. This is achieved, following Wei and Higgins (2013), by selecting plausible intervals for these elements. For the top row of matrix we set uniform prior distributions on the following intervals:
and the intervals for the remaining off-diagonal elements are
which gives implied prior distributions for the diagonal elements:
Prior distributions are placed on the standard deviations, which need to be restricted to positive values, for example , ∼ (0, 2). The prior distributions placed on the ancillary variances and correlations give implied prior distributions on the between-studies correlations and standard deviations through the formulae (10). ### initial values list(d= structure(.Data= c(NA,NA, 0.5, 0.5, 0.5, 0.5), .Dim=c(3, 2)), delta= structure(.Data= c(0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5,0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5), .Dim=c(30, 2)), psi=c(0.5, 0.5, 0.5, 0.5, 0.5, 0.5), L.u= structure(.Data= c(NA, 0.2, 0.2, 0.2, 0.2, 0.2, NA, NA, 0.2, 0.2, 0.2, 0.2, NA, NA, NA, 0.2, 0.2, 0.2, NA, NA, NA, NA, 0.2, 0.2, NA, NA, NA, NA, NA, 0.2, NA, NA, NA, NA, NA, NA), .Dim=c(6, 6))) The models reduce to the standard meta-analysis model for surrogate endpoints, such as the BRMA model, in a special case of data structure. When there are only two treatments in the network, as depicted in Figure 2 , it can be shown that model 1a reduces to BRMA. Equations (1)-(2) become 
WinBUGS code for model 1b
} } for (x in 3:nt2){ for (k in x:nt2){ s[x-1,k]<-sum(p[1:x-2,k]) lim[x-1,k]<-sqrt(1-s[x-1,k]) L.u[x-1,k]~dunif(-0.999,0.999) L[x-1,k]<-lim[x-1,k] * L.u[x-1,k] } } L.u[2,2]<-sqrt(1-pow(L[1,2],2)) L[2,2]<-L.u[2,2] for (k in 3:nt2){ s2[k]<-sum(p[1:k-1,k]) L.u[k,k]<-sqrt(1-s2[k]) L[k,k]<-L.u[k,
RELATIONSHIPS BETWEEN THE MODELS
The index (12) denoting the two treatments does not vary across studies or contrasts and hence can be dropped, resulting in equations for BRMA -equations (3.1)-(3.2) in the main manuscript, with = and = 1, 2.
SURROGACY CRITERIA
Daniels and Hughes defined the surrogacy criteria for a Bayesian meta-analytic model where the relationship between the true treatment effects on final clinical outcome 2 and the effect on the surrogate endpoint 1 was written in the form of a linear regression:
The surrogate relationship between the two treatment effects, 2 and 1 , was perfect if the intercept 0 was zero, as then a zero effect on a surrogate would imply a zero effect on the final outcome, the slope 1 should not be zero for the association to be strong, with the conditional variance 2 being zero. For the complete model see Daniels and Hughes (1997). A similar relationship and surrogacy criteria were described by Bujkiewicz et al (2015) in the framework of bivariate meta-analysis and extended by Bujkiewicz et al (2016) to multivariate meta-analysis. In the two papers the relationship between the regression parameters and the elements of the between-studies variance-covariance matrix was defined, similarly as in Bujkiewicz et al (2013) . The derived relationships in the bivariate case are
and
If the surrogacy relationship is perfect, the conditional variance is zero: 2 = 0 (Daniels and Hughes (1997), Bujkiewicz et al (2015)). Hence, from (15), 2 2 = 2 If the surrogacy relationship is perfect, the intercept is also zero: 0 = 0. The intercept can be expressed in terms of the parameters of bvMA as follows: the slope is defined by (14) and also 1 = ( 2 − 0 )∕ 1 , which leads to Figure 3 shows the predicted effects obtained from BRMA and model 2d along with the observed estimates of the effects on PFS. The improvement in predictions was not substantial due to the weak association patterns between the treatment effects on the two outcomes. 
SENSITIVITY ANALYSIS (ACRC EXAMPLE)
Sensitivity analysis was carried out investigating the effect of potentially influential observations (three studies with largest treatment effect on TR, due to no events in the control arm, were removed). Figure 4 shows the scatter plot. Tables 6 and 7 show the between studies correlations of the heterogeneity parameters. 
ILLUSTRATION USING SIMULATED DATA
Data simulation
To demonstrate scenarios where use of bvNMA methods has an advantage over the standard surrogacy models, data were simulated under different assumptions. In particular, we simulated data where the surrogate pattern across all studies and treatments differed from the patterns within treatment contrasts, which is detectable by mvNMA but not by BRMA. The treatment effects on two outcomes were simulated from a bivariate normal distribution: as in model 1a. Two sets of network data were generated, each consisting of 30 studies, three treatments and three treatment contrasts with 10 studies per contrast (AB, BC and AC), under different scenarios (illustrated in Figure 5 ). Scenario 1 was simulated assuming weak study-level surrogacy when ignoring treatment contrasts but strong study-level surrogacy within each treatment contrast, with the following parameters:
= (1, 2), = (2, 1), = (3, 3); ( , ) ∼ (0.15, 0.25), j=1,2; = = = 0.6; 1 = 0.3, 1 = 1 = 0.6, 2 = 0.3, 2 = 2 = 0.6; = = = 0.98. Scenario 2 was simulated assuming a strong study-level surrogacy relationship when ignoring treatment contrasts as well as a strong surrogate relationships within each treatment contrast, with the following parameters:
= (1, 1), = (2, 2), = (3, 3); Table 8 shows the between-studies correlations obtained by applying all models to the data simulated under all four scenarios. Additional parameters, that include the heterogeneity parameters and the implied intercepts, obtained from these analyses of all the simulated data scenarios are shown in Tables 10-13. Table 9 shows a range of statistics (described in Section 4.3.1 in the main manuscript) comparing the models in terms of their value in predicting the treatment effect on the final outcome from the treatment effect measured on the surrogate endpoint in a cross-validation procedure in all four scenarios. The results from each scenario are discussed in turn in the following sections.
Results of the analysis of the simulated data
Scenario 1
As shown in the top part of Table 8 , the between-studies correlation obtained from BRMA (across all studies) was not very high: 0.57 (95% CrI: 0.25, 0.77). Bivariate NMA with the covariance matrix varying across treatment contrasts models the data in more detail and reveals strong correlation between outcomes within the treatment contrasts, namely 0.79 (0.23, 0.99) for treatment contrast AB, 0.73 (0.01, 0.99) for BC and 0.84 (0.47, 0.98) for AC when using model 1a. Placing additional constraints on the covariance matrix by assuming second order consistency in models 1b and 1c reduced uncertainty around the correlations. Model 1d resulted in a common correlation obtained with the highest precision, however it did not take into account the differences in the between-studies variances across the treatment contrasts, in contrast to models 1a-c. The heterogeneity parameters are presented in Table 10 along with the implied intercepts, whose intervals include zero for all models apart from BRMA and models 1d and 2d (for some contrasts) which also ignore the differences in the heterogeneity patterns of the data. The right-hand-side column of Table 8 shows the across-treatment correlations indicating a weak treatment-level surrogate relationship. This is due to the differences in the study-level surrogacy patterns across the treatment contrasts as well as the small number of treatment contrasts. The top part of Table 9 lists a range of statistics indicating the superiority of the NMA methods in terms of their predictive value when applying the methods in a cross-validation procedure to data from scenario 1. The large width of the predicted interval obtained from BRMA compared to the width of the CI of the observed treatment effect estimate is due to high uncertainty, but the ratio ∕ is reduced when using NMA models. Predicted intervals obtained from NMA models are between 50% and 58% narrower compared to those obtained from BRMA. The distance between the point estimate of the observed effect from the predicted effect is also much reduced when using NMA models compared to BRMA. Figure 6 shows predicted effects obtained (a) using BRMA and (b) from model 1a obtained with higher precision.
Scenario 2
The second section of Table 8 shows the between-studies correlations for the data simulated under scenario 2. The overall correlation obtained from BRMA is high: 0.99 (95% CrI: 0.98, 1.00). Bivariate NMA with the variance-covariance matrix varying across treatment contrasts resulted in high correlations within each treatment contrast, but obtained with much higher uncertainty compared to BRMA, due to fewer data points within each treatment contrast. The heterogeneity patterns in this scenario were similar within each treatment contrast and the whole data set. The heterogeneity parameters are shown in Table  11 along with the implied intercepts which in this scenario have intervals containing zero for BRMA and most NMA models (apart from 1d and 2d which ignore some subtle differences in the heterogeneity patterns across the treatment contrasts) The across-treatment correlations in the right-hand-side column of Table 8 are obtained with high uncertainty due to the small number of treatment contrasts to estimate the correlation.
The second section of Table 9 shows the statistics for the model comparison in terms of their predictive value, obtained from the cross-validation procedure. In this scenario, the results obtained from the NMA based models appear similar to those from BRMA due to the strong study-level surrogacy across all studies as well as within each treatment contrast. Predicted intervals from NMA models were obtained with only a modest improvement in precision (likely resulting from additional borrowing of information through the indirect effects), with the reduction in uncertainty between 2% and 9% obtained from BRMA. The distance between the point estimate of the observed effect and the predicted effect is slightly increased when using NMA models 1a-c and 2a-c compared to BRMA, due to reduced data within treatment contrasts.
Scenario 3
The third section of Table 8 shows the between-studies correlations for the data simulated under scenario 3, which indicate the lack of surrogate relationship at the study level overall (BRMA) and within each treatment contrast (NMA models) as well as at the treatment level. Heterogeneity parameters and the implied intercepts are shown for completeness in Table 12 .
When the surrogate relationship is weak, in practice the cross validation procedure is not carried out. However, for completeness and the methodological considerations we present the relevant statistics in Table 9 , which for scenario 3 are in the third section of the table. The absolute bias of the predicted effects was reduced by over 50% when using the NM models compared to BRMA. In addition the uncertainty around the predicted effects was also reduced by between 52% and 61%. The assumption of normality of all data across all studies made in BRMA is unlikely to be satisfied in this data scenario, whereas assuming separate bivariate normal distributions for each subset of data within each treatment contrast, as in the NMA models, is much more plausible. This more detailed modelling of the distribution of the data, along with the added borrowing of information through indirect effects, leads to better predictions when using NMA modelling approach.
Scenario 4
The bottom section of Table 8 shows the between-studies correlations for the data simulated under scenario 4, whilst the heterogeneity parameters and the implied intercepts are shown in Table 13 . The correlation obtained from BRMA is very high; 0.86 (0.73, 0.94). However, as expected, the correlations within each contrast indicate no surrogate relationship at the study level within these contrasts. Also the interval of the implied intercept obtained from BRMA includes zero, but not the intervals obtained from the NMA models due to the lack of correlation (lack of slope in the data results in positive intercepts for all contrasts).
The bottom part of Table 9 shows the statistics for model comparison obtained from the cross-validation procedure. Despite the lack of correlation within each treatment contrast but high correlation across all studies, the predictions obtained from the NMA models were obtained with higher precision compared to BRMA reducing the absolute bias by 30% and the uncertainty around the predicted effect by between 28% and 39%. This is largely due to the impact of the indirect effects contributing to the predicted effects as well as more detailed modelling technique as explained in scenario 3. 
Between-studies correlations
ADDITIONAL SIMULATED SCENARIO: MIXED STRENGTH SURROGACY PATTERNS
Additional data scenario, illustrated in Figure 7 , was simulated assuming a strong surrogacy relationship when ignoring treatment contrasts and a mixture of either weak or strong relationships within each treatment contrast, with the following parameters:
= (1, 1), = (2, 2), = (3, 3); ( , ) ∼ (0.05, 0.15), j=1,2; = = = 0.98; 1 = 0.2, 1 = 0.25, 1 = 0.3, 2 = 0.3, 2 = 0.25, 2 = 0.2; = = 0.98 and = 0 (strong surrogacy relationships for treatment contrasts AB and AC but no relationship for BC). Table 14 shows the between-studies correlations for the data simulated under this scenario. The overall correlation obtained from BRMA is high: 0.94 (95% CrI: 0.88, 0.98). Bivariate NMA with the variance-covariance matrix varying across treatment contrasts models the data in more detail and reveals no correlation between the treatment effects on the two outcomes within the BC treatment contrast. Table 15 lists the heterogeneity parameters. Figure 8 shows the predicted effects obtained from the cross-validation using (a) BRMA and (b) NMA model 1a. When using the NMA model, predictions are obtained with higher precision for contrasts AB and AC, but not BC where there was no association between the effects on the two outcomes and which is reflected by the wide predicted intervals. The across-treatment correlations in the right-hand-side column of Table 14 are obtained with high uncertainty due to the small number of treatment contrasts to estimate the correlation. Table 16 shows the statistics for the model comparison in terms of their predictive value, obtained from the cross-validation procedure. The top panel of the table shows the statistics for all of the data. Similarly as in scenario 1, the large ratio, ∕ , comparing the width of the predicted interval obtained from BRMA with the width of the CI of the observed treatment effect estimate is reduced when using the NMA models. Predicted intervals obtained from NMA models are between 19.6% and 29.3% narrower compared to those obtained from BRMA. The distance between the point estimate of the observed effect and the predicted effect is slightly reduced when using NMA models 1a-c and 2a-c compared to BRMA. These improvements, on average, are not as strong as in scenario 1, due to poor association for the treatment contrast BC. When investigating these statistics within the treatment contrasts, the improvement is largest for contrast AC where the correlation was highest. The three bottom panels of Table 16 show similar statistics for model comparison but separately for each treatment contrast revealing the reduced uncertainty around the predicted intervals up to 50% for contrast AC where the correlation was highest. In contrast, small reduction or even increase in uncertainty of predicted effects was noted for studies in contrast BC where the correlation was weak. 
ADDITIONAL COMMENTS ON SIMULATION STUDY
In the simulation study presented in Section 6 of the main manuscript, the data were simulated from model 1a for simplicity, to allow for generating very clear and simple scenarios. Although by simulating from model 1a we do not explicitly assume second order consistency, this does not mean that the assumption is not satisfied for the simulated data and in fact the parameters we choose are such that the second order consistency is satisfied. Scenario 1 used the following parameters: = (1, 2), = (2, 1), = (3, 3); ( , ) ∼ (0.15, 0.25), j=1,2; = = = 0.6; 1 = 0.3, 1 = 1 = 0.6, 2 = 0.3, 2 = 2 = 0.6; = = = 0.9. If we denote the indexes , , , for treatments as in models 1a and 1b, as = , = and = , then the first order consistency (4)says The parameters used give: 1 − 1 = 3 − 1 = 2 = 1 and 2 − 2 = 3 − 2 = 1 = 2 . For the second order consistency (8) we have:
